Please login to the form below
Approval for S-A's prostate cancer drug
Sanofi-aventis has been granted EU approval to market its advanced prostate cancer treatment, Jevtana
Sanofi-aventis (S-A) has been granted EU approval to market its advanced prostate cancer treatment, Jevtana (cabazitaxel).
The drug has been approved in combination with prednisone/prednisolone in patients with metastatic hormone-refractory prostate cancer (mHRPC) who have previously undergone a docetaxel-containing regimen.
Jevtana had previously been given a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) – the European Medicines Agency's (EMA) committee to offer advice on medicines to be used in humans.
It has also been approved for use in the US by the Food and Drug Administration (FDA) in 2010.
Jevtana has shown positive results in the phase III TROPIC study, which involved 755 patients with mHRPC previously treated with a docetaxel-containing treatment regimen.
It found the median survival of patients receiving Jevtana was 15.1 months. This was 2.4 months longer than patients receiving mitoxantrone, a current chemotherapy treatment for prostate cancer.
Share
Related Hub content
Subscribe to our email news alerts
- Planting the Seeds for Future Women Leaders in Medicine
- FDA approves SpringWork’s Ogsiveo as first therapy for desmoid tumours
- GSK shares positive phase 3 results for Blenrep combination in multiple myeloma
- Stem cell therapy trial shows promising results for treating progressive MS
- Cancer Research UK calls on government to create ten-year cancer plan
- Risk calculator to prevent heart attacks and strokes in type 2 diabetes patients
No results were found
PMHub
Anthill Agency
Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
